The 10-day RSI Oscillator for VTAK moved out of overbought territory on November 30, 2023. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 16 instances where the indicator moved out of the overbought zone. In of the 16 cases the stock moved lower in the days that followed. This puts the odds of a move down at .
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 33 cases where VTAK's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where VTAK declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
VTAK broke above its upper Bollinger Band on November 28, 2023. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Momentum Indicator moved above the 0 level on November 24, 2023. You may want to consider a long position or call options on VTAK as a result. In of 78 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
VTAK moved above its 50-day moving average on November 24, 2023 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for VTAK crossed bullishly above the 50-day moving average on November 27, 2023. This indicates that the trend has shifted higher and could be considered a buy signal. In of 9 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where VTAK advanced for three days, in of 198 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 66 cases where VTAK Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.086) is normal, around the industry mean (25.240). P/E Ratio (0.000) is within average values for comparable stocks, (79.553). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (6.249). Dividend Yield (0.000) settles around the average of (0.019) among similar stocks. P/S Ratio (8.613) is also within normal values, averaging (44.190).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. VTAK’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VTAK’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 88, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a developer of excimer lasers for the treatment of dermatologic and cardiovascular diseases
Industry MedicalSpecialties
A.I.dvisor tells us that VTAK and BNGO have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that VTAK and BNGO's prices will move in lockstep.
Ticker / NAME | Correlation To VTAK | 1D Price Change % | ||
---|---|---|---|---|
VTAK | 100% | -3.04% | ||
BNGO - VTAK | 31% Poorly correlated | +1.21% | ||
ESTA - VTAK | 30% Poorly correlated | -4.78% | ||
PSNL - VTAK | 30% Poorly correlated | -5.13% | ||
CDNA - VTAK | 29% Poorly correlated | -0.41% | ||
PRPO - VTAK | 27% Poorly correlated | +9.39% | ||
More |
Ticker / NAME | Correlation To VTAK | 1D Price Change % |
---|---|---|
VTAK | 100% | -3.04% |
cardiovascular (undefined stocks) | 12% Poorly correlated | +1.94% |
drugs (undefined stocks) | 7% Poorly correlated | +1.33% |
medical research (undefined stocks) | 4% Poorly correlated | -0.01% |
medical service (undefined stocks) | 3% Poorly correlated | -0.22% |
treatment (undefined stocks) | 2% Poorly correlated | +1.69% |
More |